Shares of Beigene soared on Tuesday after scoring a cancer drug development deal with Novartis. The deal, announced at the annual J.P. Morgan Healthcare Conference, is worth up to $2.2 billion. Novartis will pay Beigene $650 million up front and make milestone payments to develop and sell its cancer drug, tislelizumab. Beigene will receive up … Continue reading “Beigene Inks $2.2 Billion Deal with Novartis”
